Adam Gregory - July 4, 2025 Mewburn Ellis is proud to have worked on 24 of the 100 top-selling pharmaceuticals of 2024 Mewburn Ellis works with some of the world’s most important pharmaceuticals and biologics across a ...
Adam Gregory - July 15, 2024 Mewburn Ellis is proud to have worked on 26 of the 100 top-selling pharmaceuticals of 2023 Mewburn Ellis is proud to work with some of the world’s most globally significant pharmaceuticals, ...
David Brooks - July 19, 2023 Mewburn Ellis is proud to work on 18 of the 50 top-selling pharmaceuticals of 2022 Last year we reported the unprecedented growth of the innovative pharmaceuticals industry in 2021 ...
Adam Gregory - July 22, 2022 Mewburn Ellis is proud to work on 19 of the 50 top-selling pharmaceuticals of 2021 2021 was a year of unprecedented success for the biotech and pharmaceutical industries, with the ...
Andrew Williams - October 5, 2021 Change and Opportunity: SPCs in the post-Brexit era Supplementary Protection Certificates (SPCs) are incredibly important IP rights that help ...
Sam Bailey - September 8, 2021 Could the pause in SPC-related referrals to the CJEU be permanent? As part of our Thought Leaders series, Mewburn Ellis Partner Sam Bailey considers whether a pause ...
Jacqueline Murphy - June 23, 2021 Pharma and Life Sciences Patent Extensions in Europe Our Special Report Pharma and Life Sciences Patent Extensions in Europe examines five years of data ...
Rhiannon Wescott - May 1, 2020 Can a functionally defined patent claim ‘protect’ my medicinal product? From a patent perspective this may seem like a strange question with an obvious answer; “of ...
